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Abstract
Background: Paresthesia-free cervical 10 kHz spinal cord stimulation (HF10 SCS) may constitute a novel treatment
modality for headache disorders, when pharmacological approaches fail. We report the results of a retrospective
analysis assessing the long-term safety, tolerability and efficacy of HF10 SCS in a group of patients with chronic
refractory primary headache disorders.
Findings: Four patients with chronic migraine (CM), two with chronic SUNA (Short-lasting Unilateral Neuralgiform
headache attacks with Autonomic symptoms) and one with chronic cluster headache (CCH) refractory to medical
treatments, were implanted with cervical HF10 SCS. Pre- and post-implantation data were collected from the
medical notes and from headache charts. At an average follow-up of 28 months (range: 12–42 months) we
observed an improvement of at least 50 % in headache frequency and/or intensity in all CM patients. One SUNA
patient became pain free and the other reported at least 50 % improvement in attacks frequency an duration. The
CCH patient reported a significant reduction in CH attacks duration. Two patients underwent a surgical revision due to
lead migration.
Conclusions: Paresthesia-free high cervical HF10 SCS appears to be a long-term safe and likely effective therapeutic
approach for patients with chronic refractory primary headache disorders. These results warrant further prospective
studies in larger series of patients.
Keywords: Chronic migraine, Cluster headache, SUNA syndrome, Neurostimulation, Spinal cord stimulation,
Refractory headaches
Background
Chronic daily headache (CDH) is an umbrella term that
refers to headache disorders that occur on 15 or more
days per month for more than 3 months. Primary CDH
is a major worldwide health problem that affects 3–5 %
of the population [1]. Chronic migraine (CM) is the
most common and disabling primary CDH [2, 3]. Less
frequent, but possibly more disabling primary CDH condi-
tions include the chronic forms of trigeminal autonomic
cephalalgias (TACs). This group encompasses cluster
headache (CH), short-lasting unilateral neuralgiform
headache attacks with conjunctival injection and tearing
(SUNCT), short-lasting unilateral neuralgiform headache
attacks with cranial autonomic features (SUNA), paroxys-
mal hemicrania (PH) and hemicrania continua (HC) [4].
Despite advances in the management of headache dis-
orders a significant minority of patients fails to respond
or tolerate conventional medical approaches, falling into
the category of medically “refractory” headaches. The
definition of refractory headaches is an ongoing matter
of debate and numerous attempts to draw a consensus
have been proposed [5, 6]. For this group of patients,
neurostimulation therapies targeting peripheral or cen-
tral nervous system structures have been emerging as
potential treatments [7]. Occipital nerve stimulation
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(ONS) has been used as first line neurostimulation treat-
ment for the management of various primary headache
disorders, including CM, chronic CH (CCH), HC, SUNCT
and SUNA [8, 9], based on the encouraging experience of
open-label studies. However three large randomized con-
trolled trials (RCTs) testing the efficacy of ONS for CM
prevention, displayed modest efficacy, although the studies
were criticized for poor methodological designs [10–12].
High frequency (10Khz) spinal cord stimulation (HF10
SCS) is a paresthesia-free neurostimulation therapy,
which has been shown to be effective in some chronic
pain conditions [13–15]. In view of the mixed outcome
of ONS, we began offering high cervical HF10 SCS as
part of our neurostimulation approaches to patients with
medically refractory chronic primary headache syn-
dromes and participated in a prospective exploratory
study testing cervical HF10 SCS in 17 refractory CM.
The study showed promising results in terms of toler-
ability and effectiveness of the therapy [16]. We report
here the long-term follow-up of the patients treated in
our headache centre with cervical HF10 SCS.
Methods
Participants
Seven patients with primary CDH were considered suit-
able candidates for neurostimulation and were offered a
trial of HF10 SCS therapy. All patients were diagnosed
according to the International Headache Society (IHS)
classification criteria [17] by two, experienced, headache
neurologists (SC and GL). Four had CM, two patients
had chronic SUNA and one patient had CCH. Patients
were considered refractory to conventional pharmaco-
logical treatments, according to the proposed definition
at the time of screening [5]. Botulinum toxin type A
(Botox®) was also tried according to the PREEMPT para-
digm [18] in three out of four CM patients, before consider-
ing them refractory [6]. All patients had highly disabling
headaches according to the Headache Impact Test (HIT-6).
As part of our neurostimulation pathway, patients clinically
suitable for invasive neurostimulation attend a cognitive be-
havioural therapy based implant preparation programme
[19]. Six out of seven patients completed the programme
before undergoing the stimulation trial. This study was an
audit of outcome and, as such under UK guidelines, did not
require ethics committee approval.
Implant procedure
All patients underwent a 2-weeks trial of HF10 SCS. One or
two octad leads were used according to the surgeon’ prefer-
ence. If the trial was deemed “successful”, i.e. at least 50 %
decrease in headache intensity and/or frequency, a perman-
ent implant was then performed under general anaesthesia.
The trial implant technique entails epidural lead placement
through a small skin incision under local anaesthesia
supplemented by conscious sedation. Under fluoroscopic
control, a 14-gauge Tuohy type needle was introduced at
the upper thoracic level and advanced into the epidural
space. One or two-eight-contact cylindrical leads were ad-
vanced cranially in the posterior epidural space, until the
distal tip was approximately at the C2 vertebral level (Fig. 1).
The leads were anchored and sutured to the supraspinal
ligament/paravertebral muscle fascia, connected to tempor-
ary extensions, tunneled 30 cm under the patient’s skin and
connected to a temporary external stimulator for the dur-
ation of the trial period. Multiple stimulation programmes
(frequency: 10 kHz; amplitude: 1.5–4 mA; pulse width:
30 μs) were provided to target the dorsal columns in the
area corresponding to C2-C3 vertebral level.
Subjects with a successful trial were subsequently im-
planted with an internal pulse generator. The proximal
end of the tunnelled lead(s) were connected to new sterile
extensions which provided connection to the implantable
pulse generator (IPG) (Senza™ system, Nevro Corp.,
Menlo Park, USA), which was implanted subcutaneously
either in the anterior abdominal wall or the gluteal region.
Data collection and follow-up
Baseline headache characteristics, including headache
frequency, severity, duration and medications consump-
tion, were collected retrospectively from patients’ re-
cords, headache charts, outpatient visits and telephone
clinics. Baseline headache-related disability scores were
gathered from HIT-6 questionnaires. After the operation,
patients were asked to fill a headache diary. More recently
CM- and a TACs-specific diaries were designed in our
headache centre, hence a daily headache diary and an
attack diary were respectively given to CM and TACs
patients. HIT-6 questionnaires were administered to
patients before scheduled follow-ups. The outcomes
used to assess the effectiveness of HF10 SCS for the mi-
graine patients include: change in number of headache
days and migraine days, defined according to Inter-
national guidelines [20] together with change in head-
ache severity and reduction in abortive treatment
consumption. For the TACs patients we assessed
change in number of daily attacks, change in duration
and severity of the attacks and change in medication
use. Adverse events were collected from patients’ notes.
Findings
Migraine
Four patients (3 males and 1 female; age at the time of
implant: 42–55 years old) with refractory CM had a
successful stimulation trial and underwent a full im-
plant of HF10 SCS. Table 1 summarises their baseline
pre-operative and post-operatively clinical outcomes.
All were overusing medication at the time of the surgery.
As part of our routine headache management, patients 1,
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2 and 3 withdrew analgesics for more than 2 months with-
out noticeable improvements, whereas patient 4 declined
to discontinue the use of injectable sumatriptan. Three
out of four patients had failed to respond to at least two
sets of Botulinum toxin type A (Botox®) according to the
PREEMPT paradigm [18]. Patient 1, after having failed
numerous medical treatments, was treated with occipital
nerve stimulation (ONS) in 2008. The therapy was initially
effective in reducing the severe migraine attacks but not
the background headache. Unfortunately after 3 years the
benefits of ONS declined, despite multiple reprogramming
attempts, therefore the device was explanted in September
2012. Patients 1, 2 and 4 have not been taking any oral
preventive medicines since the implant of HF10 SCS. Pa-
tient 3 was on a stable dose of pregabalin 300 mg/day and
nortriptyline 30 mg/day at baseline, with marginal benefit.
At an average follow-up of 25.3 months (range: 12–
40 months) post-implant, all patients reported remarkable
benefits, with at least a 50 % reduction in monthly number
of headache days and migraine days, which led them to
revert to an episodic headache pattern (<15 headache
days/month). This was associated with a marked reduc-
tion in number of days where patients needed to take
abortive medications. Patient 3 was also able to discon-
tinue his preventive treatments few months after device
activation. At baseline, all patients were classified as
severely disabled according to their HIT-6 scores. At the
latest available post-operative follow-up, the HIT-6 scores
were reduced in all patients; the reduction was meaningful
in two patients that rated their headache disability as of
“little and moderate impact” (patient 2 and 4). All patients
rated their overall percentage of headache improvement
between 50–100 %. Most patients reported headache
improvement a few days after the HF10 SCS trial was
commenced (patients 1, 3 and 4), whereas in patient 2
different stimulation programmes were tried before
achieving the maximum benefit.
Continuous stimulation was used in all cases. Uninten-
tionally, patients 1 and 2 switched off the device on few
occasions and experienced an exacerbation of their
headache that settled within approximately 1 to 2 weeks
after the device was switched on again. Stimulation pro-
grammes (10 kHz; 30 μs; 1.5–4 mA) were provided to
target the dorsal columns in the area corresponding to
C2–C3 x-ray vertebral body. Patients 1 and 3 had one
lead implanted and benefited from activation of the top
two contacts. Patients 2 and 4 had two leads implanted:
one at the midline and one more laterally towards the
side mostly affected by the headache: they both benefited
from alternating between the two stimulation pro-
grammes, one using the top two contacts of one lead
and the other using the top two contacts in both leads.
None of the patients reported any stimulation-induced
sensation while the device was on. There were no re-
ports of serious device-related adverse events. Patient 1
in June 2013 experienced a worsening of his headache:
high impedances on all contacts suggested system mal-
function, which was caused by lead breakage. A surgical
lead replacement led to an improvement of the headache
within 1 week of device reactivation. Patient 3 and 4 ini-
tially reported mild to moderate discomfort at the IPG
pocket, which settled respectively after 3 and 4 months.
SUNA syndrome
Two patients with chronic SUNA were treated with
HF10 SCS. The first patient was a 50 year-old woman
Fig. 1 Antero-posterior (a) and lateral (b) radiographic view of the cervical spine to demonstrate the final position of the implanted leads within
the posterior epidural space (SUNA patient, 42 months follow-up)
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Table 1 Clinical characteristics of chronic migraine patients pre- and post-high frequency cervical spinal cord stimulation treatment
















Pre Post Pre Post Pre Post Pre Post Pre Post
1 14 years 7 (including ONS) 40 Daily 5–7 8–12 2–3 7/10 7/10 8–12 (PCM, COD) 2–3 (PCM, COD) 76 65
2 3 years 9 (including Botox®) 25 Daily 10 16–24 7 7/10 4/10 15 (COD, IBP, TRA) 4 (TRA, ALM) 68 51
3 3 years 8 (including Botox®) 24 Daily 6–7 16 6–7 6/10 6/10 Daily (PCM, COD) 6–7 (PCM, COD) 74 64
4 10 years 6 (Not willing to have
Botox®)




















with an 8-year history of chronic left-sided SUNA syn-
drome according to the IHS criteria (patient 1, Table 2).
The headache was interfering significantly with her qual-
ity of life and had forced her to quit her job. In April
2013 she had a successful trial of HF10 SCS, which led
to permanent IPG (10 kHz; 30 μs; 0.4–1 mA). The therapy
provided a complete resolution of the SUNA attacks for
8 months, a part from seldom episodes of cranial auto-
nomic symptoms without headache. Subsequently the
SUNA attacks relapsed and at 28 months of follow-up
they have been occurring 10–20 times per day, lasting
2–30 s on a visual rating scale (VRS) between 5–7/10.
There have been no device-related adverse events. The
patient rated the overall improvement of the HF10 SCS
at about 70 %. She has not been taking any preventive
medication since the implant. She has been able to re-
turn to work initially part-time and then full time at the
latest available follow-up visit.
The second patient was a 43-year old woman with a
12-year history of a headache condition that fulfils the
IHS criteria for chronic migraine. Seven years ago a new
headache began. The condition was initially occurring
with an episodic pattern though after 6 months from the
onset, it became chronic, without remission periods. The
headache fulfilled the IHS criteria of chronic right-sided
SUNA syndrome (patient 2, Table 2). In July 2012 she
underwent a successful trial and subsequently a full im-
plant of HF10 SCS (10 kHz; 30 μs; 0.4–2 mA). During
the first 16 months of treatment, she reported only two
SUNA attacks/month lasting 3–5 min, moderate in
Table 2 Clinical characteristics, medical treatments and MRI outcome in Trigeminal autonomic cephalalgias patients treated with
high frequency cervical spinal cord stimulation treatment
Patient 1 Patient 2 Patient 3
Diagnosis Chronic SUNA Chronic SUNA CCH
Side of pain Left Right Left
Site of pain V1-V2-V3-C2 V3-V2-V1 V1
Pain character Stabbing Stabbing Stabbing
Attack duration 2–600 s 180–300 s 40–180 min
Attack frequency (daily) 30–50 50–60 1–10
Pain severity (VRS) 8–10/10 10/10 10/10












Migrainous symptoms Yes Yes No
Cutaneous triggers Yes No No
Background pain Yes Yes Yes
Effect of indometacin None None None

































MRI brain Normal Normal Normal
CCH chronic cluster headache; CI conjunctival injection, GONB greater occipital nerve block, IV intravenous, MCNB multiple cranial nerve block, SC subcutaneous,
SPG sphenopalatine ganglion, SUNA short-lasting unilateral neuralgiform headache attacks with autonomic symptoms, VRS verbal rating scale, V1 ophthalmic
trigeminal division, V2 maxillary trigeminal division, V3 mandibular trigeminal division
aPatient 2 declined any further pharmacological treatments
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intensity (VRS 6/10). The attacks subsided once the
stimulator was reprogrammed again. Between month 16
and month 37, two reprogramming sessions were re-
quired to maintain complete headache relief. After
42 months, she continues to report almost complete
resolution of both the SUNA attacks and the chronic
migraine, with no adverse events.
Cluster headache
One patient with CH was treated with HF10 SCS. He
was a 41-year-old man with a 7-year history of left-sided
CCH according to the IHS criteria, which became re-
fractory to medical treatments (patient 3, Table 2). He
was offered a trial with occipital nerve stimulation (ONS)
in March 2011. He became headache-free for 6 months
following the implant before the CH relapsed. Despite
re-programming, the ONS failed to improve his condi-
tion and it was discontinued. In view of the severity of
his condition, he was trialled with HF10 SCS (10 kHz;
30 μs; 0.5–1 mA). This was successful, leading to full
implant. He was then headache free for 9 months. How-
ever the CH attacks gradually came back, occurring at the
same frequency and severity of the baseline, but with a
significant reduction in duration: from 40–180 min at
baseline, to 20–35 min with active HF10 SCS. He rated
the improvement at 50 %. Since the implant, trials of so-
dium valproate and levetiracetam were implemented to
improve the condition further. Unfortunately those were
not tolerate even at low doses and therefore discontinued.
The device was switched off in one occasion for 1 month,
leading to a worsening of the CH. A lead revision was ne-
cessary after a lead migration occurred 11 months after
the surgery.
Discussion
The management of patients with primary headache
conditions refractory to pharmacological treatments
remains challenging. ONS is currently considered the
surgical treatment of choice for refractory CM and
chronic TACs [21]. However its acceptance has been
limited by the outcome of methodologically weak RCTs.
It is virtually impossible to design good, blinded con-
trolled studies for ONS because the therapy produces
paresthesia. A concern with ONS therapy is complica-
tion rates. Long-term follow-up of the largest ONS
clinical trial conducted in CM showed a total of 183 de-
vice-/procedure related adverse events during the study,
with 29 lead migrations. Other hardware-related com-
plications include IPG migration, lead breakages or
fractures, lead or extension disconnection or malfunction,
programmer malfunction or IPG malfunction. Eighty-five
adverse events (40.7 %) required surgical intervention and
18 adverse events (8.6 %) required hospitalization [22].
The high rate of hardware-related complications and
surgical revisions has recently led the European Notified
Body to remove intractable CM as an indication for ONS
therapy [23].
HF10 SCS is a paraesthesia-free system, which has
been shown to inhibit evoked afferent nociceptive inputs
by modulating wide-dynamic range neuronal activity in
the spinal cord of different animal models [24]. HF10
SCS has shown remarkable clinical efficacy in human re-
fractory back pain [13, 15]. When applied to the cervical
epidural space, it has been also reported as safe and ef-
fective in a series of subjects with upper limb neuro-
pathic pain [14]. We postulate that stimulation directly
to the dorsal columns at the level of C2-C3 vertebral
bodies with HF10 SCS may modulate the trigeminocer-
vical complex and in turn have a therapeutic effect on
primary headaches.
This case series provides initial evidence of effectiveness
of HF10 SCS in the management of refractory primary
headache disorders. In the treated CM group we observed
a significant reduction in headache and migraine days,
abortive treatment intake and headache-related disability.
The four CM patients all reverted from chronic headache
pattern to episodic. Arcioni et al reported promising
results using HF10 SCS in a small group of CM patients
with medication overuse. Fifty percent of patients reported
at least a 30 % reduction in headache days at 6 months.
Furthermore HF10 SCS therapy led to reduction of anal-
gesia consumption and disability headache-related in re-
sponders [16]. Taken together, these data indicate cervical
HF10 SCS as a new, promising treatment in refractory
CM. A caveat of the outcome analysis for both studies
could be the contribution of the medication withdrawal
effect. However in our study, three out of four patients
had undergone pre-implantation medications withdrawal
without any noticeable change in the headache pattern,
suggesting that the improvement is more likely related
to HF10 SCS, rather than to the reduction in abortive
medications intake.
To date there are no published data on effectiveness of
HF10 SCS in TACs. However, high cervical low frequency
SCS has shown promising outcome in a small series of
seven refractory CCH patients [25]. At a median follow-
up of 12 months, the Authors observed a meaningful im-
provement of the headache in all the implanted patients,
allowing reduction in medications intake. Three chronic
refractory TACs patients were treated with HF10 SCS in
this case series. We observed long-lasting and meaningful
benefits in two SUNA patients. The CCH patient, after an
initial pain-free period of a few months, experienced re-
duction in the duration but not in the intensity and fre-
quency of the attacks as the final outcome. The CCH
case had been refractory to many other treatments in-
cluding ONS, thus the partial improvement achieved
was been rated as meaningful by the patient.
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HF10 SCS may have potential clinical and technical
advantages compared to ONS. The HF10 SCS post-
implantation therapeutic effect seems to occur almost
immediately. A rapid response was noted also in the
HF10 Arcioni et al study [16] and in the Wolter et al
CCH series, using a low frequency stimulation device
[25]. In contrast, the ONS effect seems to take several
weeks or months to develop [9, 26]. This suggests that
a short trial treatment may be predictive of outcome
with central neuromodulation techniques, but not with
peripheral ONS. However, a very high positive trial rate,
like that seen in our series (100 %) as well as in the
Arcioni et al study [16], could obviate the need for a
stimulation trial, given the additional risks and incon-
venience to patients and costs to the health care system
[7]. The faster post-implant response of cervical high-
and low-frequency SCS compared to ONS, may reflect
the anatomical difference in treatment target, sugges-
ting that direct stimulation of the spinal cord may re-
cruit the trigemino-cervical complex more efficiently.
In this case-series two out of the seven patients (29 %)
developed hardware-related complications that required
additional surgery. Although based on very small num-
bers, this complication rate is in line with the one re-
ported by Arcioni et al (24 %) [16], and is lower than
reported in ONS studies (40.7 %) [22]. The epidural,
axial placement of HF10-SCS leads could be expected to
have a lower complication rate than see with ONS leads
which are placed at the mobile cranio- cervical junction.
Patients tolerated the paraesthesia-free stimulation
well. Historically, the presence of stimulation-produced
paresthesia has been considered essential for achieving
analgesia in headache neurostimulation studies [11]. The
effectiveness of a paresthesia-free neurostimulation sys-
tem implies that paresthesia sensation may not be re-
quired to achieve analgesia [27]. Since the paraesthesia
sensation associated with traditional low-frequency ONS
is at times considered uncomfortable and may lead to
therapy interruption, using a paresthesia-free device may
be better accepted by patients.
Limitations of this case series include its retrospective
nature and the absence of a control group, raising the
possibility that the effect of HF10 SCS in our patients
might be attributable to placebo or natural history.
Several observations suggest differently: a protracted
chronic phase, lack of response to several other treat-
ments, relatively high response rate, sustained long-term
improvement, and the rapid deterioration of the headache
after the device was switched off or had technical failures.
In this small case series of medically refractory primary
chronic headache subjects, the long-term HF10 SCS the-
rapy was well tolerated and beneficial, with an acceptable
safety profile (at least comparable with existing implant-
able neurostimulation devices). In view of the considerable
need for improved treatments for this highly disabled
group of patients, further prospective research in this field
is warranted.
Abbreviations
CCH, chronic daily headache; CDH, chronic daily headache; CM, chronic
migraine; HC, hemicrania continua; HF10 SCS, 10 kHz spinal cord stimulation;
HIT-6, Headache Impact Test; IHS, International Headache Society; IPG,
implantable pulse generator; ONS, occipital nerve stimulation; PH, paroxysmal
hemicrania; RCTs, randomized controlled trials; SUNA, Short-lasting Unilateral
Neuralgiform headache attacks with Autonomic symptoms; SUNCT, Short-
lasting Unilateral Neuralgiform headache attacks with conjunctival injection
and tearing; TACs, trigeminal autonomic cephalalgias; VRS, visual rating scale
Acknowledgment
The authors would like to acknowledge the contribution of Dr Sam Chong
(SC in the manuscript) for helping in the diagnosis and management of
some of the patients in this study.
Funding
This research received no specific grant.
Authors’ contributions
GL: patients diagnoses and follow-ups, data acquisition/interpretation and
manuscript drafting/revision. MT: patients follow-ups, data acquisition and
interpretation and manuscript drafting/revision. SP: analysis/interpretation of
data and manuscript drafting/revision. TS: implanted some of the patients,
analysis/interpretation of data and manuscript revision. AAK: implanted
some of the patients, analysis/interpretation of data and manuscript revision.
All authors read and approved the final manuscript.
Competing interests
Dr Lambru has received speaker honoraria and funding for travel from
Allergan, Electrocore and Nevro Corp. Dr Trimboli: nothing to declare. Dr
Palmisani received speaker fees and/or sponsorships to attend professional
meetings from Nevro Corp and Medtronic. Dr Smith has done consultancy
work for Nevro Corp and has been an investigator in Nevro sponsored
studies. Dr Al-Kaisy has received travel sponsorship and speaker fees from
Medtronic and Nevro Corp, and he is the principal investigator in separate
studies sponsored by Medtronic and Nevro Corp.
Received: 17 May 2016 Accepted: 30 June 2016
References
1. Scher AI, Stewart WF, Liberman J, Lipton RB (1998) Prevalence of frequent
headache in a population sample. Headache 38:497–506
2. Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs)
for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic
analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196
3. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P
(2015) Headache disorders are third cause of disability worldwide.
J Headache Pain 16:58
4. Headache Classification Committee of the International Headache Society
(IHS) The International Classification of Headache Disorders, 3rd edition
(beta version) (2013). Cephalalgia 33:629–808
5. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D (2006)
Towards a definition of intractable headache for use in clinical practice and
trials. Cephalalgia 26:1168–1170
6. Martelletti P, Katsarava Z, Lampl C et al (2014) Refractory chronic migraine:
a consensus statement on clinical definition from the European Headache
Federation. J Headache Pain 28:15–47
7. Lambru G, Matharu MS (2014) Peripheral neurostimulation in primary
headaches. Neurol Sci 35(Suppl 1):77–81
8. Magis D, Schoenen J (2012) Advances and challenges in neurostimulation
for headaches. Lancet Neurol 14:708–719
9. Lambru G, Shanahan P, Watkins L, Matharu MS (2014) Occipital nerve
stimulation in the treatment of medically intractable SUNCT and SUNA.
Pain Physician 17:29–41
Lambru et al. The Journal of Headache and Pain  (2016) 17:66 Page 7 of 8
10. Lipton R, Goadsby PJ, Cady R et al (2009) PRISM study: occipital nerve
stimulation for treatment-refractory migraine. Cephalalgia 29(Suppl 1):30
11. Saper JR, Dodick DW, Silberstein SD et al (2011) Occipital nerve stimulation
for the treatment of intractable chronic migraine headache: ONSTIM
feasibility study. Cephalalgia 31:271–285
12. Silberstein SD, Dodick DW, Saper J et al (2012) Safety and efficacy of
peripheral nerve stimulation of the occipital nerves for the management of
chronic migraine: results from a randomized, multicenter, double-blinded,
controlled study. Cephalalgia 32:1165–1179
13. Al-Kaisy A, Van Buyten JP, Smet I et al (2014) Sustained effectiveness of
10 kHz high-frequency spinal cord stimulation for patients with chronic, low
back pain: 24-month results of a prospective multicenter study. Pain Med
15:347–354
14. Al-Kaisy A, Palmisani S, Smith T et al (2015) The use of 10-kilohertz spinal
cord stimulation in a cohort of patients with chronic neuropathic limb pain
refractory to medical management. Neuromodulation 18:18–23
15. Van Buyten JP, Al-Kaisy A, Smet I et al (2013) High-frequency spinal cord
stimulation for the treatment of chronic back pain patients: results of a
prospective multicenter European clinical study. Neuromodulation 16:59–65
16. Arcioni R, Palmisani S, Mercieri M et al (2016) Cervical 10 kHz spinal cord
stimulation in the management of chronic, medically refractory migraine:
A prospective, open-label, exploratory study. Eur J Pain 20:70–78
17. Headache Classification Subcommittee of the International Headache
Society. The International Classification of Headache Disorders: 2nd edition
(2004). Cephalalgia 24(Suppl. 1): 9–160.
18. Aurora SK, Winner P, Freeman MC et al (2011) OnabotulinumtoxinA for
treatment of chronic migraine: pooled analyses of the 56-week PREEMPT
clinical program. Headache 51:1358–1373
19. Palmisani S, Al-Kaisy A, Arcioni R et al (2013) A six year retrospective review
of occipital nerve stimulation practice-controversies and challenges of an
emerging technique for treating refractory headache syndromes.
J Headache Pain 6:14–67
20. Silberstein S, Tfelt-Hansen P, Dodick DW et al (2008) Guidelines for
controlled trials of prophylactic treatment of chronic migraine in adults.
Cephalalgia 28:484–495
21. Martelletti P, Jensen RH, Antal A et al (2013) Neuromodulation for chronic
headaches: position statement from the European Headache Federation.
J Headache Pain 21:14–86
22. Dodick DW, Silberstein SD, Reed KL et al (2015) Safety and efficacy of
peripheral nerve stimulation of the occipital nerves for the management of
chronic migraine: long-term results from a randomized, multicenter, double-
blinded, controlled study. Cephalalgia 35:344–358
23. https://www.swissmedic.ch/recalllists_dl/10612/Vk_20141022_21-e1.pdf.
Accessed 26 June 2016.
24. Cuellar JM, Alataris K, Walker A et al (2013) Effect of high-frequency
alternating current on spinal afferent nociceptive transmission.
Neuromodulation 16:318–327
25. Wolter T, Kiemen A, Kaube H (2011) High cervical spinal cord stimulation
for chronic cluster headache. Cephalalgia 31:1170–1180
26. Burns B, Watkins L, Goadsby PJ (2009) Treatment of intractable chronic
cluster headache by occipital nerve stimulation in 14 patients. Neurology
72:341–345
27. Kapural L, Yu C, Doust MW et al (2015) Novel 10-kHz High-frequency
Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal
Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The
SENZA-RCT Randomized Controlled Trial. Anesthesiology 123:851–860
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Lambru et al. The Journal of Headache and Pain  (2016) 17:66 Page 8 of 8
